Active pharmaceutical ingredients differ by their physico-chemical properties and their bioavailability therefore varies. The most frequently used and most convenient way of administration of medicines is oral, however many drugs are little soluble in water. Thus they are not sufficiently effective and suitable for such administration. For this reason a system of Lipid Based Formulations (LBF) was developed.
Series of formulations were prepared and tested in water and biorelevant media. On the basis of selection criteria, there were selected formulations with the best emulsification potential, good dispersion in the environment and physical stability. Samples of structurally different drugs included in the Class II of the Biopharmaceutics Classification System (BCS) were obtained, namely Griseofulvin, Glibenclamide, Carbamazepine, Haloperidol, Itraconazol, Triclosan, Praziquantel and Rifaximin, for testing of maximal saturation in formulations prepared from commercially available excipients. Methods were developed for preparation of formulations, observation of emulsification and its description, determination of maximum solubility of drug samples in the respective formulation and subsequent analysis.
Saturation of formulations with drugs showed that formulations 80% XA and 20% Xh, 35% XF and 65% Xh were best able to dissolve the drugs which supports the hypothesis that it is desirable to identify limited series of formulations which could be generally applied for this purpose.
Astellas Pharma Europe BV, The Netherlands IAESTE Slovakaia DVM. Denisa Toropilová, PhD.; Tom de Vringer, PhD.
1. Driscoll, C.M.O., 2002: Lipid based formulations for intestinal lymphatic delivery. Eur. J. Pharm. Sci.,15, 405—415.
2. Hulling, Mu., Holm, R., Mullertz, A., 2013: Lipid-based formulations for oral administration of poorly water-soluble drugs. Int. J. Pharm., 453, 215—224.
3. Humberstone, A.J., Charman, W.N., 1995: Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv. Drug Deliv. Rev., 25, 103—128.
4. Charman, W.N., Porter, C.J., Mithani, S., Dressman, J.B., 1997: Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J. Pharm. Sci., 86, 269—282.
5. Kalepu, S., Manthina, M., Padavala, V., 2013: Oral lipidbased drug delivery systems — an overview. Acta Pharmaceutica Sinica B, 3, 361—372. 6. Kawabata, Y., Wada, K., Nakatani, M., Yamada, S., Onoue, S., 2011: Formulation design of poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications. Int. J. Pharm., 420, 1—10.
7. Osterberg, R.E., See, N.A., 2003: Toxicity of excipients— a food and drug administration perspective. Int. J. Toxicol., 22, 37—380.
8. Pouton, C.W., Porter, Ch.J.H., 2008: Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies. Adv. Drug Deliv. Rev., 60, 625—637.
9. Porter, C.J., Charman, W.N., 2001: In vitro assessment of oral lipid based formulations. Adv. Drug Deliv. Rev., 50, 127—147.
10. Porter, C.J., Treyaskis, N.L., Charman, W.N., 2007: Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nature Reviews Drug Discovery, 6, 231—248.
11. Pramod, K., Peeyush, K., Rajeev, K., Nitish, K., Rakesh, K., 2010: An overview of lipid based formulation for oral drug delivery. Drug Inv. Today, 2, 390—395.
12. The United States Pharmacopoeia Convention (2009) [online]. United States Pharmacopoeia excipient verification program. 35—40. http://www.usp.org/sites/default/files/usp_pdf/ EN/products/usp2008p2supplement3.pdf
13. Walle, T., Hsieh, F., DeLegge, M.H., Oatis, J.E.Jr., Walle, U.K., 2004: High absorbtion but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos., 32, 1337—1382.
14. Wilson, C.G., Mahony, B.O., 1997: The behaviour of fats and oils in the upper G.I.Tract. Bulletin Technique Gattefosse, 90, 13−18. * S.